Milestone CEO amends 679,000-share option grant

Milestone Pharmaceuticals President and CEO Joseph Oliveto filed an amended insider report updating the terms of a previously disclosed stock option grant.

Rhea-AI Filing Summary

Milestone Pharmaceuticals President and CEO Joseph Oliveto filed an amended insider report updating the terms of a previously disclosed stock option grant. The filing shows an employee stock option to purchase 679,000 common shares at an exercise price of $1.96 per share.

The amendment states that the exercise price on the initial filings was incorrectly stated and is now corrected. One-fourth of the option shares will vest on February 2, 2027, with one thirty-sixth of the remaining shares vesting each month afterward, as long as Oliveto continues to provide service.

Insider Trade Summary

Grant/Award: 679,000 shares

Grant/Award 1 txn

Insider Oliveto Joseph

Role President and CEO

Type	Security	Shares	Price	Value
Grant/Award	Employee Stock Option (right to buy)	679,000	$0.00	$0.00

Holdings After Transaction: Employee Stock Option (right to buy) — 679,000 contracts (Direct)

Footnotes (2)

1. F1. The exercise price on the initial filings was incorrectly stated.
2. F2. One-fourth (1/4th) of the shares subject to the option vest on February 2, 2027, and one thirty-sixth (1/36th) of the remaining shares subject to this option shall vest each month thereafter, subject to the Reporting Person continuing to provide service through each such date.

FAQ

What insider transaction did Milestone Pharmaceuticals (MIST) report?

Milestone Pharmaceuticals reported an amended insider filing for President and CEO Joseph Oliveto. It corrects the terms of a previously reported employee stock option grant covering 679,000 common shares, clarifying the exercise price and detailed vesting schedule associated with the award.

How many stock options did the Milestone Pharmaceuticals CEO receive?

The CEO received an employee stock option covering 679,000 common shares of Milestone Pharmaceuticals. These options are scheduled to vest over time, with an initial cliff vesting on February 2, 2027, followed by monthly vesting of the remaining portion, contingent on continued service.

What is the exercise price of the CEO’s stock options at Milestone Pharmaceuticals?

The employee stock option for the Milestone Pharmaceuticals CEO has an exercise price of $1.96 per share. The amended Form 4 explains that the exercise price was incorrectly stated in the initial filings and is now accurately reflected as $1.96 for the 679,000-option grant.

Why did Milestone Pharmaceuticals file an amended Form 4/A for its CEO?

Milestone Pharmaceuticals filed an amended Form 4/A because the exercise price on the CEO’s initial option filings was incorrectly stated. The amendment corrects this pricing error while reaffirming the 679,000-share option size and the associated time-based vesting schedule tied to continued service.

What is the vesting schedule for the CEO’s 679,000 stock options at Milestone (MIST)?

The CEO’s 679,000 stock options vest over several years. One-fourth of the option shares vest on February 2, 2027. The remaining shares then vest in equal monthly installments, with one thirty-sixth of the remainder vesting each month, assuming continuous service through each vesting date.

Does the amended filing indicate any sale of Milestone Pharmaceuticals shares by the CEO?

The amended filing describes an employee stock option grant and its corrected exercise price, not a sale of shares. It details 679,000 options at a $1.96 exercise price and a multi-year vesting schedule, focusing on the terms of the award rather than any disposition of stock.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 02/05/2026 - 04:30 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Oliveto Joseph

(Last) (First) (Middle)

C/O MILESTONE PHARMACEUTICALS INC.

1111 DR. FREDERIK-PHILIPS BLVD, STE 420

(Street)

MONTREAL A8 H4M 2X6

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Milestone Pharmaceuticals Inc. [ MIST ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	President and CEO

3. Date of Earliest Transaction (Month/Day/Year)
02/02/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)
02/04/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Employee Stock Option (right to buy)	$1.96(1)	02/02/2026		A		679,000		(2)	02/02/2036	Common Shares	679,000	$0	679,000	D

Explanation of Responses:

1. The exercise price on the initial filings was incorrectly stated.

2. One-fourth (1/4th) of the shares subject to the option vest on February 2, 2027, and one thirty-sixth (1/36th) of the remaining shares subject to this option shall vest each month thereafter, subject to the Reporting Person continuing to provide service through each such date.

	/s/ Joseph Oliveto	02/05/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.